Brief: An2 Therapeutics Commences Phase 3 Part Of Phase 2/3 Clinical Trial Evaluating Epetraborole For Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease
13/09/2023 12:10
Sept 13 (Reuters) - AN2 Therapeutics Inc ANTX.O :
* AN2 THERAPEUTICS COMMENCES PHASE 3 PART OF PHASE 2/3
CLINICAL
TRIAL EVALUATING EPETRABOROLE FOR TREATMENT-REFRACTORY
MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG DISEASE
* AN2 THERAPEUTICS INC- TOPLINE PHASE 2 TRIAL RESULTS
EXPECTED IN
SUMMER 2024
Source text for Eikon: ID:nBw6nCFMba
Further company coverage: ANTX.O
((Reuters.Brief@thomsonreuters.com;))
Recent news on AN2 Therapeutics
See all newsBrief: AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(C)(4)
Brief: An2 Therapeutics Announces Extension Of Funding For Tuberculosis Research Collaboration With Gsk
AN2 Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
AN2 Therapeutics Q2 net loss widens on higher R&D costs
AN2 Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview